Clinical trials: Inflammatory Myelopathies
Rare Diseases, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
- Trial name
- NCT07247292
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Neuromyelitis Optica Spectrum Disorder
Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica Spectrum Disorders (NMOSD) is characterized by the pathogenic anti-AQP4 antibody, which can be produced by specific plasma cells.
- Trial name
- NCT02893111
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica
Safety of Therapeutic Step-down in Neuromyelitis Optica
Neuromyelitis Optica (NMO) is a neuroinflammatory disease related to multiple sclerosis (MS). It affects young subjects and causes a lot of handicap without treatment.
- Trial name
- NMO (NCT05155644)
- Where
- France
- Volunteers
- 947 people
- Sponsor
- University Hospital, Strasbourg, France
Poliomyelitis
Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine
This study will be an open-label phase III randomized clinical trial comparing different combinations and regimens of polio vaccines.
- Trial name
- NCT02291263
- Testing
- bOPV/IPV (6 weeks), bOPV/IPV (14 weeks), bOPV/IPV (6 & 14 weeks)
- Where
- Bangladesh
- Volunteers
- 738 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules
This is a phase IV open-label randomized clinical trial that will compare intestinal and humoral immunity in infants receiving inactivated poliovirus vaccine (IPV) and two or three doses of bivalent oral poliovirus vaccine (bOPV).
- Trial name
- NCT02412514
- Testing
- bOPV (three dose), bOPV (two dose), IPV
- Where
- Bangladesh
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants
The purpose of this phrase III clinical trial is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in a '2+1'sequential schedule with bivalent oral poliovirus vaccine in 2-month-old…
- Trial name
- NCT03822767
- Testing
- sIPV-sIPV-bOPV vaccination schedule, wIPV-wIPV-bOPV vaccination schedule
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Polio Immunity
Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine.
- Trial name
- NCT07688369
- Testing
- Recombinant Poliomyelitis Vaccine (rPV), Inactivated Poliomyelitis Vaccine (IPOL)
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT04155424
- Testing
- Eculizumab
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 5 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Infant, Healthy
Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®
The purpose of the study is to provide data on the safety and immunogenicity of Pediacel® to allow its use as a fourth dose administered to 11-18 months old toddlers at the same time as Prevenar®.
- Trial name
- NCT00355654
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, DT3aP-HBs-IPV
- Where
- 84 sites in Germany
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants
The purpose of this study is to generate immunogenicity and safety data of an investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine compared to a control vaccine, Infanrix hexa™ when given along with Prevenar™ and Rotarix™…
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01177722
- Testing
- DTaP-IPV-Hep B-PRP-T Vaccine, DTaP-Hep B-IPV vaccine
- Where
- 2 sites in Colombia, Costa Rica
- Volunteers
- 1,375 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Varicella, Measles
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Primary Objective: To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the antibody response rates to measles…
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432042
- Testing
- ProQuad®, Infanrix® hexa
- Where
- 50 sites in Germany, Italy
- Volunteers
- 955 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Poliomyelitis
Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization
This study is a supplementary study of an already finished randomised, double-blinded, and placebo controlled phase 2 clinical trial of an Sabin strain inactivated poliovirus vaccine (sIPV) manufactured by Sinovac Biotech Ltd.…
- Trial name
- NCT04618783
- Testing
- Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses, Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses, Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
Pathologic-MRI Findings in Atypical IIDD
Our objective is to describe the pathologic and MRI findings in a series of patients with presumed demyelinating lesion of the central nervous system.
- Trial name
- IIDD (NCT03121105)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions.
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Optic Neuritis
- Trial name
- NCT01623076
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder
Biomarkers in Autoimmune Disease of Nervous System
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves.
- Conditions
- Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis, Guillain-Barre Syndrome
- Trial name
- NCT06502015
- Testing
- biomaker levels
- Where
- China
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
HTLV-I Infections, HTLV-II Infections
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
- Conditions
- HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2
- Trial name
- NCT03226119
- Testing
- MP Diagnostics HTLV Blot 2.4
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- MP Biomedicals, LLC
Tuberculosis, Polio
Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan
Routine childhood immunization (RCI) in Pakistan is well below the recommended coverage of 90% with rates as low as 16% in certain regions (Pakistan DHS 2012-3).
- Conditions
- Tuberculosis, Polio, Diphtheria, Pertussis
- Trial name
- NCT03341195
- Testing
- SMS messages and automated calls
- Volunteers
- 3,850 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Neuromyelitis Optica
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD19 CAR-T therapy for patients with relapsed or refractory Neuromyelitis Optica, and to evaluate the…
- Trial name
- NCT05828212
- Testing
- CAR-T cells injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
Diphtheria, Tetanus
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
The present clinical study will assess the immunogenicity and reactogenicity of the subsequent administration of Aventis Pasteur's DTacP-IPV//PRP~T combined vaccine (PENTAVAC™/PENTAXIM), as a three-dose primary vaccination in 6…
- Conditions
- Diphtheria, Tetanus, Polio, Pertussis
- Trial name
- NCT00254917
- Testing
- Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine
- Where
- Philippines
- Volunteers
- 387 people, healthy volunteers welcome
- Sponsor
- Sanofi
Haemophilus Influenzae Type b, Diphtheria
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine
To assess the safety and reactogenicity of the DTPa-HBV-IPV/Hib vaccine and DTPa-IPV/Hib vaccine. This DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or Placebo.
- Conditions
- Haemophilus Influenzae Type b, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00325143
- Testing
- DTPa-HBV-IPV/Hib, DTPa-IPV/Hib vaccine
- Where
- 3 sites in Singapore
- Volunteers
- 702 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline